Last reviewed · How we verify
NCT06621277: JUMP_START
JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors
trial testing No intervention in Gastrointestinal Cancer in 250 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | University Hospital Heidelberg |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 October 2023 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- No intervention
- Tailored counseling programs (Phase 2)
Conditions studied
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Sponsor
University Hospital Heidelberg
Who can join
18 and older, any sex, with Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
JUMP\_START aims to assess the needs of individuals aged ≤ 50 years with gastrointestinal (GI) tumors and implement a tailored support and counseling program at the University Hospital Heidelberg and the National Center for Tumor Diseases (NCT). In phase 1A, 12-15 individuals aged ≤ 50 years with GI tumors will be interviewed via telephone using semi-structured interviews to obstain a detailed understanding of the life situation, the burdens, and the care situation within the structures of the NCT Heidelberg. In phase 1B, the care networks of young patients with GI tumors beyond the NCT, including the analysis of changes and important access routes/possible gatekeepers, will be explored using so-called ego-centered network analyses, in comparison with patients who received a GI tumor diagnosis after the age of 50. In response to the results of phase 1A and 1B, the care services for young patients with GI tumors will be optimized, and tailored counseling programs will be developed in phase 2. These project phases will be accompanied by Quality of Life assessments using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires. All patients with GI tumors (regardless of potential inclusion in phase 1A or 1B) will receive the EORTC questionnaires once. In phase 2, Quality of Life will be assessed every 6 months.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimization of multiprofessional care for young colorectal cancer patients: a qualitative Study.
Xu K, Flock C, Kaunath K, Schmitt N, et al · · 2025 · PMID 40421958 · DOI 10.1093/oncolo/oyaf082
Verify or expand the search:
- PubMed search for NCT06621277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Gastrointestinal Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
- NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
- NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting
Other University Hospital Heidelberg trials
Trials by the same sponsor.
- NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
- NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
- NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
- NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
- NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06621277 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06621277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing